A Framework for Fitness-for-Purpose and Reuse in Computational Phenotyping
November 17, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
No Data Available.
Synonyms :
labetalol
Class :
Antihypertensive and alpha/beta-blockers
Brand Name :
No Data Available.
Synonyms :
labetalol
Class :
Antihypertensive and alpha/beta-blockers
Dosage Forms & Strengths
Injectable solution
5mg/ml
Tablet
100mg
200mg
300mg
100
mg
Orally
every 12 hrs
initially; increased up to100 mg for 12hrs every 2-3 days Usual dosage range: 200-400 mg orally every 12hrs Do not exceed 2400 mg per day
20
mg
Intravenous (IV)
over 2 minutes initially
then 40-80 mg IV for every 10min
Do not exceed 300 mg per day
Dosage Forms & Strengths
Injectable solution
5mg/ml
Tablet
100mg
200mg
300mg
0.4 - 1
mg/kg
per hour by continuous IV infusion
do not exceed 3 mg/kg per hour
13
mg/kg
Orally
once a day
or divided for every 12hr
do not exceed 1200 mg per day
bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib
bradycardia-Causing Agents may enhance the bradycardic effect of ponesimod
may increase the bradycardic effect of bradycardia-causing agents
may have an increased bradycardic effect when combined with fingolimod
may have an increased bradycardic effect when combined with ponesimod
may have an increased bradycardic effect when combined with siponimod
may decrease the diagnostic effect when combined with benzylpenicilloyl polylysine
may have an increased hypertensive effect when combined with alpha1-blockers
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may enhance the hypotensive effect of phosphodiesterase 5 Inhibitors
may increase the vasoconstricting effect of Ergot Derivatives
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
clozapine: they may increase the bradycardic effect of Bradycardia-Causing Agents
secretin: they may increase the bradycardic effect of Bradycardia-Causing Agents
sincalide: they may increase the bradycardic effect of Bradycardia-Causing Agents
aclidinium: they may increase the bradycardic effect of Bradycardia-Causing Agents
cimetropium: they may increase the bradycardic effect of Bradycardia-Causing Agents
eluxadoline: they may increase the bradycardic effect of Bradycardia-Causing Agents
glycopyrrolate: they may increase the bradycardic effect of Bradycardia-Causing Agents
ipratropium: they may increase the bradycardic effect of Bradycardia-Causing Agents
levosulpiride: they may increase the bradycardic effect of Bradycardia-Causing Agents
atropine: they may increase the bradycardic effect of Bradycardia-Causing Agents
oxatomide: they may increase the bradycardic effect of Bradycardia-Causing Agents
potassium chloride: they may increase the bradycardic effect of Bradycardia-Causing Agents
revefenacin: they may increase the bradycardic effect of Bradycardia-Causing Agents
tiotropium: they may increase the bradycardic effect of Bradycardia-Causing Agents
umeclidinium: they may increase the bradycardic effect of Bradycardia-Causing Agents
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
deferiprone: it may increase the bradycardic effect of Bradycardia-Causing Agents
thalidomide: it may increase the bradycardic effect of Bradycardia-Causing Agents
dexamethasone: it may increase the bradycardic effect of Bradycardia-Causing Agents
azelastine: it may increase the bradycardic effect of Bradycardia-Causing Agents
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
bradycardia causing agents increase the arrhythmia-causing effect of fexinidazole
may decrease the bronchodilatory effect
may increase the hypertensive effect of Monoamine Oxidase inhibitors
may increase the hypertensive effect of Monoamine Oxidase inhibitors
may decrease the bronchodilatory effect of each other when combined
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may decrease the vasoconstriction effects
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may decrease the vasoconstricting effect when combined with alpha1-agonists
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may reduce the vasoconstriction-inducing action
may decrease the vasoconstricting effect when combined with alpha1-agonists
bunazosin (Not available in the United States)
may decrease the vasoconstricting effect when combined with alpha1-agonists
may decrease the vasoconstricting effect when combined with alpha1-agonists
may decrease the vasoconstricting effect when combined with alpha1-agonists
may decrease the vasoconstricting effect when combined with alpha1-agonists
When dexrabeprazole and labetalol is used together, this leads to reduction in the dexrabeprazole’s metabolism
may decrease the vasoconstricting effect when combined with alpha1-agonists
may have an increased bradycardic effect when combined with other bradycardia-causing agents
labetalol : it may increase the toxic effect of Methemoglobinemia Associated Agents
labetalol : it may increase the toxic effect of Methemoglobinemia Associated Agents
labetalol : it may increase the toxic effect of Methemoglobinemia Associated Agents
labetalol : it may increase the toxic effect of Methemoglobinemia Associated Agents
labetalol : it may increase the toxic effect of Methemoglobinemia Associated Agents
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
alpha-1 blocker: they may increase the therapeutic effect of acetylcholine inhibitors
alpha-1 blocker: they may increase the therapeutic effect of acetylcholine inhibitors
When labetalol is used together with adenine, this leads to a reduction in the labetalol’s metabolism
may decrease the vasoconstricting effect when combined with alpha1-agonists
ketamine: it may increase the risk of adverse effects with CYP3A4 inhibitors
ketamine: it may increase the risk of adverse effects with CYP3A4 inhibitors
ketamine: it may increase the risk of adverse effects with CYP3A4 inhibitors
ketamine: it may increase the risk of adverse effects with CYP3A4 inhibitors
ketamine: it may increase the risk of adverse effects with CYP3A4 inhibitors
may decrease the constriction effects of alpha-1 agonist
may decrease the constriction effects of alpha-1 agonist
hydrocodone/chlorpheniramine/pseudoephedrine
may decrease the vasoconstriction effects of alpha/beta agonists
may increase the bradycardia effect
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
bradycardia-causing agents increase the efficacy of ivabradine
may increase the hypotensive effect
may enhance the hypotensive effect of Alpha1-Blockers
may enhance the hypotensive effect of Alpha1-Blockers
may enhance the hypotensive effect of Alpha1-Blockers
may enhance the hypotensive effect of Alpha1-Blockers
may enhance the hypotensive effect of Alpha1-Blockers
may decrease the bronchodilatory effect of beta-blockers
may decrease the bronchodilatory effect of beta-blockers
may decrease the bronchodilatory effect of beta-blockers
may decrease the bronchodilatory effect of beta-blockers
may decrease the bronchodilatory effect of beta-blockers
acrivastine and pseudoephedrine
may increase the vasoconstrictive effect of alpha/beta agonists
may increase the bradycardic effect of bradycardia-causing agents
may increase the hypotensive effect of calcium channel blockers
may increase the hypotensive effect of calcium channel blockers
may enhance the orthostatic effect of beta blockers
may enhance the bradycardic effect of bradycardia-causing agents
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the hypotensive effect of blood pressure lowering agents
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the vasoconstricting effect when combined with alpha-/beta-agonists
may decrease the vasoconstricting effect of Alpha-/Beta-Agonists
alkalinizing agents: they may enhance the serum concentration of Alpha or Beta-Agonists
alkalinizing agents: they may enhance the serum concentration of Alpha or Beta-Agonists
alkalinizing agents: they may enhance the serum concentration of Alpha or Beta-Agonists
alkalinizing agents: they may enhance the serum concentration of Alpha or Beta-Agonists
alkalinizing agents: they may enhance the serum concentration of Alpha or Beta-Agonists
may increase the bradycardic effect of each other
may increase the effects of bosentan by pharmacodynamic synergism
midodrine: they may increase the bradycardic effect of Bradycardia-Causing Agents
ozanimod: they may increase the bradycardic effect of Bradycardia-Causing Agents
tofacitinib: they may increase the bradycardic effect of Bradycardia-Causing Agents
it may diminish the excretion rate when combined with Growth hormone agonist, resulting in an enhanced serum level
it may diminish the excretion rate when combined with Growth hormone agonist, resulting in an enhanced serum level
it may diminish the excretion rate when combined with Growth hormone agonist, resulting in an enhanced serum level
it may diminish the excretion rate when combined with Growth hormone agonist, resulting in an enhanced serum level
It may enhance the risk of adverse effects when combined with Androgens
It may enhance the risk of adverse effects when combined with Androgens
may decrease the vasoconstricting effect when combined with alpha1-agonists
may have an increased bradycardic effect when combined with other bradycardia-causing agents
may have an increased orthostatic hypotensive effect when combined with alpha1-blockers
may have an increased orthostatic hypotensive effect when combined with alpha1-blockers
may have an increased orthostatic hypotensive effect when combined with alpha1-blockers
amifampridine: they may increase the bradycardic effect of Bradycardia-Causing Agents
dipyridamole: they may increase the bradycardic effect of Bradycardia-Causing Agents
mirabegron: they may increase the bradycardic effect of Bradycardia-Causing Agents
nitroglycerin: they may increase the bradycardic effect of Bradycardia-Causing Agents
succinylcholine: they may increase the bradycardic effect of Bradycardia-Causing Agents
topiramate: they may increase the bradycardic effect of Bradycardia-Causing Agents
fluorouracil: they may increase the bradycardic effect of Bradycardia-Causing Agents
methoxsalen: they may increase the bradycardic effect of Bradycardia-Causing Agents
porfimer: they may increase the bradycardic effect of Bradycardia-Causing Agents
may have an increased orthostatic hypotensive effect when combined with alpha1-blockers
may have an increased orthostatic hypotensive effect when combined with alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may have an increased orthostatic hypotensive effect when combined with alpha1-blockers
may decrease the vasoconstricting effect when combined with alpha1-agonists
When labetalol is used together with oliceridine, this leads to reduction in oliceridine’s metabolism
May diminish the effects of indomethacin by pharmacodynamic antagonism
may decrease the bronchodilatory effect of beta-blockers
may decrease the bronchodilatory effect of beta-blockers
may decrease the bronchodilatory effect of beta-blockers
pamidronate: it may enhance the bradycardic effect of Bradycardia-Causing Agents
valerian: it may enhance the bradycardic effect of Bradycardia-Causing Agents
zoledronic acid: it may enhance the bradycardic effect of Bradycardia-Causing Agents
Action:
Labetalol is a mixed alpha- and beta-adrenergic receptor blocker used primarily to treat hypertension. It exerts its effect by blocking beta-1 and beta-2 receptors (which reduces heart rate and myocardial contractility) and alpha-1 receptors (which causes vasodilation and decreases peripheral vascular resistance). The combined blockade leads to lower blood pressure without significantly reducing cardiac output or heart rate, making it suitable in both acute and chronic hypertensive settings.
Spectrum:
Labetalol is primarily used for the management of hypertension, including chronic hypertension and hypertensive emergencies. It is especially effective in treating severe hypertension during pregnancy, such as in cases of preeclampsia and eclampsia. Additionally, labetalol may be used perioperatively to help control blood pressure during surgical procedures.
Adverse drug reactions:
Frequency defined
>10%
Tingling sensation of scalp
Nausea
Fatigue
Dizziness
Lightheadedness
1-10%
Absence of ejaculation
Elevated serum blood urea nitrogen (BUN)
Bronchospasm
Elevated serum creatinine
Dyspnea
Pruritus
Rash
Altered taste sense
Ventricular arrhythmia
Congestion of nasal sinus
Orthostatic hypotension
Paresthesia
Elevated liver enzymes
Diaphoresis
Edema
Frequency Not Defined
Bradycardia
Alopecia
Angioedema
Cholestatic jaundice
Depression
Blackbox warnings:
Alert if you have bronchospastic disease, heart failure, or hepatic injury.
Contraindication/caution
Labetalol should be avoided if the patient is allergic and have asthma, severe bradycardia, uncontrolled heart failure, very low blood pressure, or fainting due to slow heartbeats.
It should be used with caution in individuals with pregnant or planning to be pregnant, requiring eye surgery, or elderly due to potential adverse effects.
Monitor for common side effects like dizziness, drowsiness, nausea, and skin redness. while the serious side effects may include slow heart rate, difficulty breathing, and liver complications.
Pregnancy warnings:
AU TGA pregnancy category: C
US FDA pregnancy category: C
Breastfeeding warnings:
The release of the drug into the human breastmilk is known
Pregnancy Categories:
Pharmacology:
Labetalol is a beta blocker used to treat hypertension by slowing down heart rate and reducing force by decreasing its effects on the central nervous system and reducing the likelihood of neuropsychiatric side effects.
Pharmacodynamics:
Labetalol is a prolonged-acting antihypertensive which lowers blood pressure by counteracting adrenergic receptors and typically administered twice daily. Patients with bronchospasms should avoid it unless other options are ineffective or untolerable.
Pharmacokinetics:
Absorption
It is absorbed rapidly, peak plasma concentrations reach in 1 to 2 hours
Distribution
Volume of distribution shows 5 to 7 L/kg
Metabolism
First-pass metabolism in the liver by conjugation with glucuronic acid to produce inactive metabolites.
Elimination and Excretion
The metabolites excreted in the urine, with 55% to 75% of the dose excreted unchanged or as metabolites.
Action and spectrum:
Labetalol with both alpha and beta-blocking properties blocks adrenergic receptors by reducing the effects of adrenaline and stress hormones making it effective in managing hypertension and other comorbid conditions.
Administration:
Labetalol tablets can be taken orally with water during meals while injections are administered intravenously for severe hypertension.
Initial oral dose is 100 mg twice daily with dosage adjusted based on blood pressure levels.
Patient information leaflet
Generic Name: labetalol
Pronounced: luh-BET-uh-lol
Why do we use labetalol?
Labetalol is primarily used for the treatment of hypertension. It is effective in managing chronic hypertension, hypertensive emergencies, and is commonly prescribed for severe hypertension during pregnancy, including in cases of preeclampsia and eclampsia. It is also utilized perioperatively to maintain blood pressure stability during surgical procedures. Due to its combined alpha- and beta-blocking properties, labetalol offers both cardiac and vascular benefits in controlling blood pressure.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
